In South-Eastern Europe, and Western and Central Europe, amphetamine-type stimulants (ATS) use and health harm remain mainly linked to amphetamine and are relatively low compared to other regions.Amphetamines are the third most common stimulant drugs group in Europe after cocaine and “ecstasy”.…
Methamphetamine and other ATS remain the leading substances for which people seek drug treatment in East and South-East Asia.The number of people receiving treatment for ATS use, mainly methamphetamine, has remained stable or declined in the majority of reporting countries – with the exception of…
The use of amphetamines has distinct regional patterns; past-year use is generally higher among men (0.85 per cent) than women (0.34 per cent) globally.The largest markets for ATS, mainly methamphetamine, remain East and South-East Asia and North America. The highest past-year use of amphetamines…
“Ecstasy” use remains highest in high income countries and parts of Asia.Past-year use of "ecstasy" globally is estimated at 0.4 per cent among those aged 15-64. Use is higher among men (0.54 per cent) than women (0.26 per cent), but the difference is not as pronounced as for other drugs (for…
Australia and New Zealand have the highest global annual prevalence of use of "ecstasy", where it is mostly used in capsule and crystal form.In Australia, the use and availability of "ecstasy" declined during the COVID-19 pandemic but have started to increase again in 2023 (while not yet reaching…
“Ecstasy” use remains concentrated in Europe (mainly Western and Central Europe)Use is significantly higher in Western and Central Europe than in Eastern and South-Eastern Europe, both in terms of prevalence (1.2 per cent vs. 0.4 per cent) and number of users (nearly 4 million versus less than 800,…
The illicit ketamine market has expanded beyond Asia, with rising use and emerging harms in new regions.Once concentrated in East and South-East Asia, several countries with time-series data (for example, the United Kingdom, Australia or the United States) have recorded an increase in the use of…
As intensive methamphetamine use has increased in both Australia and New Zealand, associated health harms have also increased.In Australia, hospitalizations and the number of people in drug-related treatment related to methamphetamine use have increased over the long-term, although recent data…
Methamphetamine-related harms show mixed trends across North America.In Mexico, methamphetamine harms have increased in recent years, reflected in a growing number of people entering drug-related treatment for the substance – though recent data suggest possible signs of stabilization.In contrast,…
In Australia, past-year methamphetamine use has declined since 2004, but among people who still used the drug, there are signs of increases in intensive use patterns.A similar trend is observed in New Zealand, where the police characterize the methamphetamine market as saturated. Intensive use of…
Similarly to most internationally controlled drugs, the use of NPS among adolescents is higher than among the general population, but the difference between adolescent boys and girlsis lower for NPS than for controlled drugs.Limited data suggest that NPS use is generally higher among school…
Limited data suggest stable or declining NPS use among young people, with some exceptions.Time-series data on NPS use among young people are scarce and largely limited to high-income countries.Where data are available, the use of NPS is generally stable or declining, as corroborated by recent…
